Clinical trials: Circulating Tumor Cell;
Neoplastic Cells, Circulating, Pancreatic Cancer
Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the United States. The high mortality for these tumors is primarily attributed to the late stage in which most patients are diagnosed, leading to…
- Conditions
- Neoplastic Cells, Circulating, Pancreatic Cancer, Biological Markers
- Trial name
- NCT02974764
- Testing
- No intervention/exposures
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Lung Cancer
Circulating and Imaging Biomarkers to Improve Lung Cancer Management and Early Detection
Validation of biomolecular markers in the circulation and radiomic features are the focus of this project.The aim is to assess the role of molecular and cellular biomarkers (exosomes antigens, Circulating tumor cells - CTCs…
- Trial name
- SMAC-2 (NCT04315753)
- Testing
- LDCT (Low Dose CT)
- Where
- Italy
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Oropharynx Squamous Cell Carcinoma
SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
SURVEILLE-HPV - A new post therapeutic surveillance strategy for HPV-driven oropharyngeal cancer based on HPV Circulating DNA measures.
- Trial name
- SURVEILLE-HPV (NCT05582122)
- Testing
- HPV16 Ct-DNA dosing
- Where
- 16 sites in France
- Volunteers
- 420 people
- Sponsor
- UNICANCER
Breast Neoplasms
Concordance Between Liquid and Tissue Biopsy
Tissue biopsy is a procedure to remove a piece of tissue (sample of cells) from the body to be analyzed in a laboratory, and it is commonly performed to confirm diagnosis of a patient with symptoms of breast cancer recurrence.
- Trial name
- NCT04241237
- Testing
- Blood Draw
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Melanoma, Circulating Tumor Cell
Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology
Several studies conducted over the past decade have shown that Circulating tumor cells (CTCs) can be used as a marker for predicting disease progression and survival in patients with early or metastatic cancer.
- Trial name
- EXPEVIVO-CTC (NCT03797053)
- Testing
- Biological sample
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Tumor, Adult
Circulating Tumor Cells in Solid Tumors
The purpose of this study is to identify circulating tumor cells in patients with solid tumors. Quantify and characterize these cells, collect patient information in regards to the patient's cancer.
- Trial name
- NCT03161821
- Testing
- Observational
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Oropharyngeal Squamous Cell Carcinoma, Human Papillomavirus (HPV)
The Role of Circulating Tumour DNA in Head and Neck Cancer
Cancers of the throat, oropharyngeal squamous cell carcinoma (OPSCC), are highly prevalent across Scotland. Over the past 10 years, both global and Scottish cases of OPSCC have increased, particularly those associated with human…
- Trial name
- NCT05539638
- Where
- 5 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- University of Edinburgh
Non Small Cell Lung Cancer, Advanced Solid Tumor
Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid biopsy and tissue analyses.
- Trial name
- CIRCULAR (NCT04912687)
- Testing
- EGFR gene mutation analysis on liquid biopsy
- Where
- 9 sites in France
- Volunteers
- 581 people
- Sponsor
- Institut Bergonié
Rectal Neoplasms, Circulating Tumor Cells
Detection of CTCs in Stage III Rectal Cancer Patients Undergoing Neoadjuvant Therapy
The purpose of this study is to evaluate the value of dynamic change in detecting CTCs in peripheral blood from stage III rectal cancer patients undergoing neoadjuvant Folfox treatment and chemoradiotherapy,before and after…
- Trial name
- NCT02554448
- Testing
- ISET system
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Prostate Cancer Metastatic
Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer
As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed.
- Trial name
- NCT03089099
- Testing
- Blood drawing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Circulating Tumor Cells, Pancreatic Adenocarcinoma
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
Histological proof is a crucial and necessary step for appropriate care in oncology. In the case of pancreatic cancer, histological proof from pathological analysis of the surgical specimen is very rare due to the limited number…
- Conditions
- Circulating Tumor Cells, Pancreatic Adenocarcinoma, Circulating Tumor DNA (KRAS), CA 19.9
- Trial name
- CTC-Pancreas (NCT02072616)
- Testing
- Pancreatic adenocarcinoma diagnosis
- Where
- France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Rouen
Metastatic Breast Cancer, Benign Breast Disease
China CellSearch Study
The study is designed to confirm the current indication (below) of the CellSearch® Circulating Tumor Cell Kit in metastatic breast cancer (MBC) patients for use of the kit in China.
- Trial name
- NCT01116869
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Medical, China
Non-Small Cell Lung Cancer
Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer
Successful treatment of non-small cell lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in your body and protect your normal tissue.
- Trial name
- NCT00603057
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- University of Michigan Rogel Cancer Center
Peripheral T-cell Lymphoma, NK/T-Cell Lymphoma
Circulating Tumor DNA in Peripheral T-cell Lymphomas
The aim of this study is to evaluate the feasibility of circulating tumor DNA (ctDNA) measurement in blood plasma for the applicability in prognostication, treatment evaluation and measurable residual disease (MRD) surveillance…
- Trial name
- CIRCULATE (NCT06362148)
- Testing
- Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay, 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Primary Central Nervous System Lymphoma (PCNSL)
Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
This project aims to establish and prospectively register a longitudinal, multimodal biobank for primary central nervous system lymphoma (PCNSL).
- Trial name
- CLIMB (NCT07842835)
- Testing
- High-dose methotrexate-based therapy, Bruton tyrosine kinase inhibitor-based therapy
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Xiaohui Ren
HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer…
- Conditions
- HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients
- Trial name
- NCT02035813
- Testing
- Ribociclib, Eribulin
- Where
- Germany
- Volunteers
- 116 people
- Sponsor
- Prof. Wolfgang Janni
Esophageal Squamous Cell Carcinoma
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.
- Trial name
- NCT05426850
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer
Women with metastatic breast cancer, receiving first line treatment of any kind (chemotherapy, endocrine treatment or treatment with antibodies) will be included in this trial.
- Trial name
- CTC-MBC (NCT01322893)
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Lund University Hospital
Melanoma (Skin Cancer)
ctDNA for Risk Stratification in Melanoma
This study examines circulating tumor DNA (ctDNA) as a biomarker in patients with primary melanoma, prior to surgical excision. The hypothesis is that ctDNA may be detectable in pre-operative blood samples from patients with…
- Trial name
- NCT07531121
- Where
- Denmark
- Volunteers
- 296 people
- Sponsor
- Herlev and Gentofte Hospital
Diffuse Large B-cell Lymphoma
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
Within this exploratory multicohort phase II trial, SAKK aims to evaluate a PET/CT and ctDNA oriented therapy in DLBCL in order to test the following working hypothesis.
- Trial name
- NCT04604067
- Testing
- Acalabrutinib
- Where
- 19 sites in Italy, Switzerland
- Volunteers
- 260 people
- Sponsor
- Swiss Cancer Institute